Arena FDA Panel Set for Sept. 16

Xconomy San Diego — 

Arena Pharmaceuticals (NASDAQ: ARNA), the San Diego-based developer of a new obesity drug, said today that the FDA has notified the company of tentative plans for an advisory committee meeting to discuss its treatment on September 16. Arena first sought clearance from the FDA to start selling lorcaserin in the U.S. in December, and the agency has set a deadline of October 22 to complete its review.  The FDA usually follows the advice of its advisory panels, although it isn’t required to do so.

By posting a comment, you agree to our terms and conditions.

Comments are closed.